The Pharmaletter

One To Watch

avm_company

AVM Biotechnology

AVM Biotechnology is a Seattle, USA-based biotech firm developing AVM0703.

"AVM0703 is a purer and loaded formulation of dexamethasone, which has been used at lower doses since 1958 for other purposes. Our supra-pharmacologic dose has a novel mechanism of action (MOA) to mobilize the body’s own natural supercharged immune cells that are ten times more activated than ordinary immune cells."

Want to Update your Company's Profile?


Latest AVM Biotechnology News

More AVM Biotechnology news >